LifeMD expands access to Lilly’s self-pay GLP-1 medicines, enabling option to dispense and ship directly to patients nationwide
Eligible patients prescribed Zepbound® or Foundayo® through LifeMD can now receive authentic Lilly medicines at Lilly 's self-pay prices through LifeMD 's affiliated pharmacy
NEW YORK, Nov. 05, 2026 (GLOBE NEWSWIRE) -- LifeMD, Inc. (Nasdaq: LFMD), a leading provider of virtual primary care, today announced an arrangement with Eli Lilly and Company (Lilly) that enables LifeMD 's affiliated pharmacy to directly dispense and ship Lilly 's self-pay GLP-1 medicines, including Zepbound® (tirzepatide) and Foundayo® (orforglipron), to eligible patients across the United States.
Under the arrangement, eligible patients prescribed a Lilly medication by a LifeMD-affiliated healthcare provider following an independent clinical evaluation can purchase that medication at Lilly 's established self-pay price directly through LifeMD. Prescriptions will be fulfilled and shipped by LifeMD 's licensed mail-order pharmacy, creating a seamless patient experience from consultation and prescribing to fulfillment and home delivery. The program includes both Zepbound® and Foundayo®. Lilly and LifeMD will continue to explore opportunities to expand access to additional medicines in the future.
The expansion further strengthens LifeMD 's vertically integrated care platform, combining virtual healthcare, clinical support, pharmacy services, and medication fulfillment within a single patient experience. It also reflects a shared commitment to improving access to evidence-based obesity treatment through a transparent and convenient care pathway.
"Lilly is committed to helping eligible patients access authentic, FDA-approved medicines, " said Laura Steele, Group Vice President, U.S. Cardiometabolic Health at Eli Lilly and Company. "Working with platforms like LifeMD can help simplify the patient experience by enabling access where patients are seeking care. "
"This expansion represents another important step in our mission to make obesity care more accessible , " said Justin Schreiber, Chairman and Chief Executive Officer of LifeMD. "By integrating Lilly 's self-pay medicines directly into our pharmacy operations, we 're creating a more seamless experience for patients while strengthening our vertically integrated care model. Most importantly, we 're helping more patients access these therapies through a simple, and transparent pathway. "
Patients can access the program through LifeMD 's virtual care platform. As with all care delivered through LifeMD, prescriptions are issued only when a LifeMD-affiliated healthcare provider independently determines that treatment is clinically appropriate following a medical evaluation. Lilly self-pay medications available through the program are offered on a cash-pay basis and are not billed to insurance.
LifeMD believes the arrangement further enhances the Company 's ability to support long-term growth in obesity care while improving patient access to branded GLP-1 therapies.
About LifeMD, Inc.
LifeMD® is a leading provider of virtual primary care. LifeMD offers telemedicine, access to laboratory and pharmacy services, and specialized treatment across more than 200 conditions, including primary care, men 's and women 's health, weight management, and hormone therapy. The Company leverages a vertically integrated, proprietary digital care platform, a 50-state affiliated medical group, a state-of-the-art affiliated pharmacy, and a U.S.-based patient care center to increase access to high-quality and affordable care. For more information, please visit lifemd.com.
Forward-Looking Statements
This news release includes forward-looking statements within the meaning of Section 27A of the Securities Act of 1933, as amended; Section 21E of the Securities Exchange Act of 1934, as amended; and the safe harbor provision of the U.S. Private Securities Litigation Reform Act of 1995. Forward-looking statements contained in this news release may be identified by the use of words such as: “believe,” “expect,” “anticipate,” “project,” “should,” “plan,” “will,” “may,” “intend,” “estimate,” “predict,” “continue,” and “potential,” or, in each case, their negative or other variations or comparable terminology referencing future periods. Examples of forward-looking statements include, but are not limited to, statements regarding our financial outlook and guidance, short and long-term business performance and operations, future revenues and earnings, regulatory developments, legal events or outcomes, ability to comply with complex and evolving regulations, market conditions and trends, new or expanded products and offerings, growth strategies, underlying assumptions, and the effects of any of the foregoing on our future results of operations or financial condition.
Forward-looking statements are not historical facts and are not assurances of future performance. Rather, these statements are based on our current expectations, beliefs, and assumptions regarding future plans and strategies, projections, anticipated and unanticipated events and trends, the economy, and other future conditions, including the impact of any of the aforementioned on our future business. As forward-looking statements relate to the future, they are subject to inherent risk, uncertainties, and changes in circumstances and assumptions that are difficult to predict, including some of which are out of our control. Consequently, our actual results, performance, and financial condition may differ materially from those indicated in the forward-looking statements. These risks and uncertainties include, but are not limited to, “Risk Factors” identified in our filings with the Securities and Exchange Commission, including, but not limited to, our most recently filed Annual Report on Form 10-K, Quarterly Reports on Form 10-Q, and any amendments thereto. Even if our actual results, performance, or financial condition are consistent with forward-looking statements contained in such filings, they may not be indicative of our actual results, performance, or financial condition in subsequent periods.
Any forward-looking statement made in the news release is based on information currently available to us as of the date on which this release is made. We undertake no obligation to update or revise any forward-looking statement, whether as a result of new information, future events, or otherwise, except as may be required under applicable law or regulation.
Disclaimer
Lilly has not authorized the content of this advertisement.
Media Contact:
Investor Contact:
© 2026 GlobeNewswire, Inc. All Rights Reserved.
